Blog
About

0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Effect of Cholesterol-Lowering Treatment on Coronary Heart Disease Morbidity and Mortality: The Evidence from Trials, and Beyond

      Cardiology

      S. Karger AG

      Serum cholesterol, Low-density-lipoprotein cholesterol, Coronary heart disease, Diet, Drugs, Adverse effects

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Evidence from controlled clinical trials shows convincingly that reducing serum cholesterol levels by diet or drug treatment reduces the incidence of coronary heart disease. On a population basis, the most important effect of cholesterol lowering might be postponement of the first symptoms of disease rather than postponement of death, because most cardiac deaths occur at an advanced age. No enhanced cancer mortality is seen either in populations with low serum cholesterol levels or in patients who, through a genetic defect, have a low-density-lipoprotein cholesterol of zero. This makes it unlikely that cholesterol-lowering treatment as such promotes cancer. Still, specific side effects and toxicity of drugs need careful scrutiny, and diet remains the treatment of choice for mild hypercholesterolemia.

          Related collections

          Author and article information

          Journal
          CRD
          Cardiology
          10.1159/issn.0008-6312
          Cardiology
          S. Karger AG
          978-3-8055-5278-3
          978-3-318-00092-4
          0008-6312
          1421-9751
          1990
          1990
          12 November 2008
          : 77
          : Suppl 4
          : 8-13
          Affiliations
          Department of Human Nutrition, Wageningen Agricultural University, Wageningen, The Netherlands
          Article
          174678 Cardiology 1990;77:8–13
          10.1159/000174678
          2073675
          © 1990 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 6
          Categories
          HMG CoA Reductase Inhibitors: New Horizons in the Management of Hypercholesterolemia

          Comments

          Comment on this article